This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-16 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
This was a first step away from in-vivo pregnancy testing and initiated a series of improvements in pregnancy testing leading to the contemporary at-home testing. Direct measurement of antigens, such as hCG, was made possible after the invention of the radioimmunoassay in 1959. Radioimmunoassays require sophisticated apparatus and special radiation precautions and are expensive. Organon International obtained the first patent on a home pregnancy test in 1969, two years after product designer Margaret Crane noticed that the laboratory testing procedure was relatively simple and made a prototype. The product became available in Canada in 1971, and the United States in 1977, after delays caused by concerns over sexual morality and the ability of potentially pregnant women to perform the test and cope with the results without a doctor. Another home pregnancy testing kit was based on the work of Judith Vaitukaitis and Glenn Braunstein, who developed a sensitive hCG assay at the National Institutes of Health. That test went onto the market under the name e.p.t. in 1978. e.p.t. originally stood for "Early Pregnancy Test" but was later changed to "Error Proof Test". In the 1970s, the discovery of monoclonal antibodies led to the development of the relatively simple and cheap immunoassays, such as agglutination-inhibition-based assays and sandwich ELISA, used in modern home pregnancy tests. Tests are now so cheap that they can be mass-produced in a general publication and used for advertising.
=== Hormonal === Because women have a higher incidence of AD than men, it has been thought that estrogen deficiency during menopause is a risk factor. In a 2025 analysis of the Canadian Longitudinal Study on Aging, earlier age at menopause was linked with lower cognitive performance.
=== Dietary challenges === Adhering to the GFD can negatively impact those with coeliac disease, requiring major changes for an individual and their family. The restrictive nature of the GFD can lead to no longer enjoying food and pressure to be constantly vigilant about diet. The social life of those with coeliac disease is also negatively affected by the GFD. Cross-contamination—gluten-free food coming into contact with gluten—is a common worry for those eating away from home. Eating out may cause anxiety as it requires disclosing dietary restrictions and risking potential cross-contamination. Receiving a diagnosis of coeliac disease and the dietary changes required to manage the disorder can affect a person's relationship with food and lead to disordered eating as well as anxiety and depression. A diagnosis of coeliac disease can carry stigma, which may affect individuals' ability to seek help or disclose their condition when needed. Accessing gluten-free food can be a burden due to limited availability and variety, as well as higher costs compared to gluten-containing foods. Over the past ten years, the costs of gluten-free food have decreased; however, it remains significantly more expensive than gluten-containing food. There has been an increase in the popularity of the GFD among those without coeliac disease, which has improved the availability of gluten-free foods.
Basement membranes are characteristic of eumetazoans, including diploblastic animals, and have also been identified in homoscleromorph sponges. The homoscleromorph were found to be sister to diploblasts in some studies, making the membrane originate once in the history of life. But more recent studies have disregarded diploblast-homoscleromorph group, so other sponges may have lost it (most probable) or the origin in the two groups may be separate.
Einsteinium was first identified in December 1952 by Albert Ghiorso and co-workers at University of California, Berkeley in collaboration with the Argonne and Los Alamos National Laboratories, in the fallout from the Ivy Mike nuclear test. The test was done on November 1, 1952, at Enewetak Atoll in the Pacific Ocean and was the first successful test of a thermonuclear weapon. Initial examination of the debris from the explosion had shown the production of a new isotope of plutonium, 244Pu, which could only have formed by the absorption of six neutrons by a uranium-238 nucleus followed by two beta decays.
Sources: en.wikipedia.org
Maintaining potential control in in situ measurements preserves the electrochemical environment at the electrode–electrolyte interface, thereby keeping the double layer and ongoing electron-transfer reactions intact at a given electrode potential.
==== Administering the department ==== Although the Ministry of Defence already had its own "Management Audit" system, Heseltine insisted on introducing his own version of the MINIS system which he had introduced at the Environment. The Ministry of Defence had a budget of £17 million per annum, and employed 246,000 civilians as well as 300,000 in uniform. Whereas the Department of the Environment had 66 directorates, Defence had 156, each headed by a two-star officer or a civil servant of equivalent seniority. The organisation chart took months to design and covered four large sheets of paper. In the event Heseltine was too preoccupied by the political matters to pay much attention to the MINIs reports which had taken so long to produce. Heseltine disliked dealing with paperwork, and insisted on having plenty of time to take decisions, and that all reports sent to him had to be first run past one of his advisers for comments. Staff numbers fell by 20,000 (one in twelve) during Heseltine's time at Defence, and many services were privatised, including the Royal Ordnance Factories whilst the Royal Navy Dockyards at Devonport and Rosyth were put under private management. The three separate service ministries (Admiralty, War and Air) had merged into a single Ministry of Defence in 1981. Heseltine drew up plans on a flight back from Kuwait to merge the services further, so that the three chiefs of staff reported directly to the Chief of Defence Staff instead of being treated as colleagues, whilst some supply services were to be merged.
Peas also contain high levels of dietary fibre, which consists of cellulose, gums, hemicellulose, pectin, mucilage, lignin, and resistant starches. Dry pea has 17-27% dietary fibre depending on their cultivar, environment, and global growing region. In terms of sugars, pea seeds contain 5-6% sucrose and raffinose. Sucrose ranges from 2.2% to 2.6%, whereas oligosaccharides, such as stachyose have a range of 1.3-3.2%, verbascose 1.2-4.0%, and raffinose 0.2-1.0% depending on cultivar and environment. The fat content of pea seeds ranges from 1.2% to 1.8% depending on the cultivar and about 25% of fatty acids are composed of oleic acid (18:1) and 50% of linoleic acid (18:2). Pea seeds are also a rich source of minerals and vitamins, such as folic acid, riboflavin, pyridoxine, and niacin.
In his book TiHKAL (Tryptamines I Have Known and Loved) and other publications, Alexander Shulgin lists DMT's dose as greater than 350 mg orally, 60 to 100 mg intramuscularly, subcutaneously, or via smoking, and 4 to 30 mg by intravenous injection. He also reported that doses of 150 to 350 mg or even up to 1,000 mg orally and a dose of 100 mg buccally produced no effects, whereas doses of 20 to 80 mg intramuscularly, 30 to 100 mg smoked, and 15 to 30 mg intravenously were all active in producing effects. In terms of intramuscular injection, threshold effects occur at a dose of 30 mg and full effects occur at a dose of 50 to 100 mg by this route. Similarly, the dose for full effects with subcutaneous injection is likewise 60 to 100 mg. With regard to intravenous injection, a dose of 4 mg was indistinguishable from placebo, 8 mg produced physical effects but no psychoactive effects, 15 mg produced threshold psychedelic effects, and 30 mg produced strong psychedelic effects. Shulgin lists the duration of parenteral DMT alone as up to 1 hour. In other more recent publications, different dose ranges of inhaled DMT of 2 to 100 mg or 15 to 60 mg have been described and typical doses have been reported to be 40 to 50 mg. Concerning intravenous injection and based on contemporary clinical studies, 15 mg has been described as a low dose, 25 mg as an intermediate or "good effect" dose, and 30 mg as a high or "ego-dissolution" dose. There may be a ceiling in the intensity of DMT's effects however, with saturation reached at doses of 15 to 20 mg.
Sources: en.wikipedia.org
The first one to systematically expand and correct the chemical potentials of Bohr's atomic theory was Walther Kossel in 1914 and in 1916. Kossel explained that in the periodic table new elements would be created as electrons were added to the outer shell. In Kossel's paper, he writes: This leads to the conclusion that the electrons, which are added further, should be put into concentric rings or shells, on each of which ... only a certain number of electrons—namely, eight in our case—should be arranged. As soon as one ring or shell is completed, a new one has to be started for the next element; the number of electrons, which are most easily accessible, and lie at the outermost periphery, increases again from element to element and, therefore, in the formation of each new shell the chemical periodicity is repeated. In a 1919 paper, Irving Langmuir postulated the existence of "cells" which we now call orbitals, which could each only contain eight electrons each, and these were arranged in "equidistant layers" which we now call shells. He made an exception for the first shell to only contain two electrons. The chemist Charles Rugeley Bury suggested in 1921 that eight and eighteen electrons in a shell form stable configurations. Bury proposed that the electron configurations in transitional elements depended upon the valence electrons in their outer shell. He introduced the word transition to describe the elements now known as transition metals or transition elements.
Homology - the structure is similar between the two species because of shared ancestry and common genetics. Convergence - the structure is similar between the two species because of independent adaptation to common environmental pressures. Understanding which characteristics and structures belong to each type is an important part of understanding plant evolution. The evolutionary biologist relies on the plant morphologist to interpret structures, and in turn provides phylogenies of plant relationships that may lead to new morphological insights.
In 1995, Ice-T had a recurring role as vengeful drug dealer Danny Cort on the television series New York Undercover, co-created by Dick Wolf. His work on the series earned him the 1996 NAACP Image Award for Outstanding Supporting Actor in a Drama Series. In 1997, he co-created the short-lived series Players, produced by Wolf. This was followed by a role as pimp Seymour "Kingston" Stockton in Exiled: A Law & Order Movie (1998). These collaborations led Wolf to add Ice-T to the cast of Law & Order: Special Victims Unit. Since 2000, he has portrayed Odafin "Fin" Tutuola, a former undercover narcotics officer transferred to the Special Victims Unit. In 2002, the NAACP awarded Ice-T with a second Image Award, again for Outstanding Supporting Actor in a Drama Series, for his work on Law & Order: SVU. Around 1995, Ice-T co-presented a UK-produced magazine television series on black culture, Baadasss TV. In 1997, Ice-T had a pay-per-view special titled Ice-T's Extreme Babes which appeared on Action PPV, formerly owned by BET Networks. In 1999, Ice-T starred in the HBO film Stealth Fighter as a United States Naval Aviator who fakes his own death, steals an F-117 stealth fighter, and threatens to destroy United States military bases. He also acted in the film Sonic Impact, released the same year. Ice-T made an appearance on the comedy television series Chappelle's Show as himself presenting the award for "Player Hater of the Year" at the "Player-Haters Ball", a parody of his own appearance at the Players Ball. He was dubbed the "Original Player Hater".
== Structure == PGLYRP2 has one canonical carboxy-terminal catalytic peptidoglycan-binding type 2 amidase domain (also known as a PGRP domain) with predicted peptidoglycan-binding and catalytic cleft with walls formed by α-helices and the floor by a β-sheet. PGLYRP2 also has a long N-terminal segment that comprises two thirds of the PGLYRP2 sequence, has two hydrophobic regions, is unique and not found in other mammalian PGLYRP1, PGLYRP3, and PGLYRP4 and in invertebrate PGRPs, and contains intrinsically disordered region with hepatitis B virus (HBV) DNA-binding domain. The C-terminal segment is also longer than in other mammalian PGLYRPs. PGLYRP2 has two pairs of cysteines in the PGRP domain that are conserved in all human PGRPs and are predicted to form two disulfide bonds. Human PGLYRP2 is glycosylated and secreted, and forms non-disulfide-linked homodimers. PGLYRP2, similar to all other amidase-active PGRPs (invertebrate and vertebrate), has a conserved Zn2+-binding site in the peptidoglycan-binding cleft, which is also present in bacteriophage type 2 amidases and consists of two histidines, one tyrosine, and one cysteine (His411, Tyr447, His522, Cys530 in human PGLYRP2).
intermetallic A type of alloy that forms an ordered solid-state compound between two or more metallic elements. Intermetallics are generally hard and brittle, and have useful mechanical properties at high temperatures.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.